Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial

Brigham and Women's Hospital, Boston, MA 02115, USA.
Cancer Prevention Research (Impact Factor: 4.44). 04/2009; 2(4):310-21. DOI: 10.1158/1940-6207.CAPR-08-0206
Source: PubMed


The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer. The trial randomized 2,035 subjects to receive either placebo, celecoxib 200 mg twice daily, or celecoxib 400 mg twice daily. The primary study safety and efficacy analyses involved 3 years of treatment. The results showed significant antitumor effect but also indicated increased cardiovascular adverse events in patients treated with celecoxib compared with placebo. A total of 933 patients participated in an extension of the Adenoma Prevention with Celecoxib Trial, with a planned total treatment and surveillance duration of 5 years. Study medication was stopped early, resulting in a median treatment duration of 3.1 years for those with a year 5 colonoscopy. Patients treated on the placebo arm had a cumulative adenoma incidence of 68.4% over 5 years of observation. This figure was 59.0% (P < 0.0001) for those receiving low-dose celecoxib, and 60.1% (P < 0.0001) for those receiving high-dose celecoxib. The cumulative incidence of advanced adenomas over 5 years was 21.3% of those taking placebo, 12.5% (P < 0.0001) of those taking low dose celecoxib and 15.8% (P < 0.0001) of those taking high-dose celecoxib. Investigator reported treatment emergent adverse events were similar across all treatment groups for categories including renal and hypertensive events and gastrointestinal ulceration and hemorrhage events. For a category composed of cardiovascular and thrombotic events, the risk relative to placebo was 1.6 (95% confidence interval, 1.0, 2.5) for those using 200 mg twice daily celecoxib and 1.9 (95% confidence interval, 1.2, 3.1) for those using 400 mg twice daily celecoxib. Secondary analysis showed an interaction between a baseline history of atherosclerotic heart disease and study drug use with respect to cardiovascular and thrombotic adverse events (P = 0.004). These results confirm the inhibitory effect of celecoxib on colorectal adenoma formation, and provide additional safety data indicating an elevated risk for cardiovascular and thrombotic adverse events, particularly for patients with preexisting atherosclerotic heart disease.

Download full-text


Available from: Donya Bagheri,
  • Source
    • "The majority of clinical trials examining the anti-proliferative effects of anti-inflammatory agents have been conducted in bowel and lung cancer. Cox2 inhibitors prevent the progression of bowel polyps [74] and they have demonstrated a chemoprotective role in patients at high risk of developing lung cancer [75]. However, large studies have not found improvement in survival or oncological outcomes when celecoxib is added to palliative lung cancer-treatment regimens [76] [77]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of the perioperative period during cancer surgery and its impact on patients' long-term cancer outcomes are of increasing interest. Anticipation and prevention of perioperative immunosuppression and targeted therapeutic interventions that translate to reduced cancer recurrence are increasingly being explored. These interventions may focus on reducing the systemic inflammatory response, the regional lymphatic flow induced by surgical inflammation and exposure to perioperative immunosuppressive agents. The challenge has been to provide evidence-based links between these hypothesised cancer 'reducing' strategies, our knowledge of cancer biology and tangible long-term clinical outcomes of improved recurrence-free and overall survival. Anaesthesiologists caring for patients with cancer may preferentially employ regional anaesthesia techniques and anti-inflammatory agents to minimise perioperative immunosuppression and preserve perioperative homeostasis. However, prospective trials powered for long-term cancer outcomes are necessary to provide an evidence base before these strategies are to be recommended for routine clinical practice.
    12/2013; 27(4):427-439. DOI:10.1016/j.bpa.2013.10.003
  • Source
    • "In it, the chemopreventive effect on adenoma incidence remained with celecoxib use, with an RR of 0.71 for the low dose and 0.62 for the high dose. However, the cardiovascular risk also remained, with an RR of 1.6 (1–2.5) for the 200 mg dose and 1.9 (1.2–3.1) for the 400 mg dose [22]. The last study, PreSAP trial, ran parallel to the APC [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer (CRC) is presently one of the most common causes of cancer-related death in our setting and affects a great number of people each year. Screening strategies are commonly used but they do not seem enough to avoid CRC development or prevent completely its mortality. Because of this fact other prevention strategies have gained interest in recent years. Chemoprevention seems to be an attractive option in this setting and several drugs have been studied in this field. This review is focused on salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs) and cycloxygenase-2 inhibitors (COXIBs), whose mechanism of action could be directly related to colon cancer chemoprevention.
    The Scientific World Journal 04/2012; 2012(15):327341. DOI:10.1100/2012/327341 · 1.73 Impact Factor
  • Source
    • "Rofecoxib, a highly specific COX-2 inhibitor, was withdrawn from the world market because of an increased rate of cardiovascular events in patients with colorectal polyps [48]. Celecoxib was also shown to augment cardiovascular and thrombotic risk in colorectal adenoma patients, especially in the subgroup suffering from pre-existing atherosclerotic heart disease [49]. Moreover, inhibition of COX-2 activity has been reported to exacerbate brain inflammation by increasing glial cell activation [50]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Celecoxib, a highly specific cyclooxygenase-2 (COX-2) inhibitor has been reported to have COX-2-independent immunomodulatory effects. However, celecoxib itself has only mild suppressive effects on arthritis. Recently, we reported that a 4-trifluoromethyl analogue of celecoxib (TFM-C) with 205-fold lower COX-2-inhibitory activity inhibits secretion of IL-12 family cytokines through a COX-2-independent mechanism that involves Ca2+-mediated intracellular retention of the IL-12 polypeptide chains. In this study, we explored the capacity of TFM-C as a new therapeutic agent for arthritis. To induce collagen-induced arthritis (CIA), DBA1/J mice were immunized with bovine type II collagen (CII) in Freund's adjuvant. Collagen antibody-induced arthritis (CAIA) was induced in C57BL/6 mice by injecting anti-CII antibodies. Mice received 10 μg/g of TFM-C or celecoxib every other day. The effects of TFM-C on clinical and histopathological severities were assessed. The serum levels of CII-specific antibodies were measured by ELISA. The effects of TFM-C on mast cell activation, cytokine producing capacity by macrophages, and neutrophil recruitment were also evaluated. TFM-C inhibited the severity of CIA and CAIA more strongly than celecoxib. TFM-C treatments had little effect on CII-specific antibody levels in serum. TFM-C suppressed the activation of mast cells in arthritic joints. TFM-C also suppressed the production of inflammatory cytokines by macrophages and leukocyte influx in thioglycollate-induced peritonitis. These results indicate that TFM-C may serve as an effective new disease-modifying drug for treatment of arthritis, such as rheumatoid arthritis.
    Arthritis research & therapy 01/2012; 14(1):R9. DOI:10.1186/ar3683 · 3.75 Impact Factor
Show more